This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Simmunext Biotherapeutics


Simmunext Biotherapeutics is developing an off-the-shelf product to support or bypass adoptive cancer therapy (ACT) based on a filament-like semi-flexible PIC polymer backbone to which immune-modulating proteins are coupled. Using this technology platform, called ‘immunofilaments’, we generate bioconjugates that are able to stimulate immune cells in a manner similar to natural antigen presenting cells. We obtained preclinical proof of concept convincingly and are preparing for FIH studies. 

We're bringing you

  • Startup Spotlight Pitch Competition